According to Vision Research Reports, the dental bone grafts and substitutes market was valued at USD 645.2 million in 2021 and it is predicted to surpass around USD 1.52 billion by 2030 with a CAGR of 9.99% from 2022 to 2030.
According to Vision Research Reports, the dental bone grafts and substitutes market was valued at USD 645.2 million in 2021 and it is predicted to surpass around USD 1.52 billion by 2030 with a CAGR of 9.99% from 2022 to 2030.
The increasing number of dental implant surgeries, the growing target population, technological advancement in synthetic bone grafts, and new product launches are the major growth propelling factors for the market.
According to the Population Reference Bureau 2018 statistics, by 2050, from 13 countries to around 82 countries across the world are anticipated to have more than 20% of the geriatric population (65 years and above). Thus, perpetual growth in the population aged 60 years and above is anticipated to result in an increased prevalence of periodontal diseases. These aforementioned factors are driving the market.
Full Report is Ready | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/39235
Moreover, the rising adoption of synthetic bone grafts over autografts and allografts due to advantages such as lesser chances of disease transmission, and better acceptance is further propelling the market. Moreover, growing medical tourism in developing countries, as well as a growing number of periodontists and oral surgeons, are some other factors propelling growth. Countries such as South Korea, India, and Turkey are constantly gaining popularity in dental tourism due to cheaper costs and advanced treatment options.
The onset of the pandemic significantly affected the sales of dental bone graft products as almost all the dental services were halted for a major part of 2020. However, as control measures and vaccines were effectively introduced globally, essential dental treatments and sales of dental products rose to assist in a significant recovery. Many key players in the market have reported high growth for their dental implants and biomaterial products in 2021.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 645.2 million |
| Revenue Forecast by 2030 | USD 1.52 billion |
| Growth rate from 2022 to 2030 | CAGR of 9.99% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Material type, application, end-use, region |
| Companies Covered | Geistlich Pharma AG; Medtronic; Zimmer Holding Inc; RTI Surgical, Inc.; Dentsply Sirona etc; BiohorizonsIph, Inc. (US); Orthogen, LLC (US) |
Material Type Insights
Xenograft product segment held the largest revenue share of 21.2% in 2021. Based on product, the market is segmented into xenograft, allograft, and synthetic material. A xenograft is a bone taken from an animal source such as a bovine and implanted into the human body. The most commonly used xenograft is Bio-Oss. Key industry players are taking the initiative to launch new xenograft products for better penetration. For instance, in 2019 Marks Biotech Inc. launched Novobone, a xenograft in order to improve its bone grafting product portfolio. The other key players include ACE Surgical, BioHorizons, etc.
The synthetic segment is expected to exhibit lucrative growth over the forecast period. The growth can be attributed to its higher osteoconductivity, hardness, and better acceptance. There are various types of synthetic materials available in the market such as ceramic, polymer-based, BMPs, etc. The chance of disease transmission is low with synthetic grafting as compared to xenograft & allograft, which is further boosting the growth. Moreover, increasing demand to develop biocompatible grafts to reduce adverse reactions is driving this segment.
Increasing uses of synthetic grafts with HAP, TCP which has shown better biocompatibility as compared to others is fueling the growth. The polymer-based grafts also have shown good biocompatibility. The industry players are continuously trying to develop new products with better biocompatibility, bioactivity, and suitable mechanical properties. For instance, in June 2019, Biogennix received 510(K) clearance from USFDA for Agilon, which is fully biocompatible with human bone. The aforementioned factors are boosting revenue.
Full Report is Ready | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39235
Application Insights
The socket preservation application segment held the largest revenue share of 28.8% as of 2021. The application segment includes Ridge Augmentation, Sinus Lift, Periodontal Defect Regeneration, Implant Bone Regeneration, and Socket PreservationIt is a method that is used to decrease bone loss after tooth extraction from tooth socket in the alveolar bone. An escalating number of dental implant surgeries and increasing awareness among people about oral health care are the driving factors for the growth of this segment.
Ridge augmentation also held a significant revenue share owing to its quick recovery time and painless procedure. The demand for this procedure is increasing in order to achieve long-term survival and successful implant placement. Moreover, alveolar volume gain is also possible with the help of ridge augmentation, thus boosting the growth. Some of the most common grafting materials used arePuros by Zimmer Biomet, Bio-Oss by Osteohealth, INFUSE bone graft by Medtronic, etc.
End-use Insights
The dental clinics end-use segment held the largest revenue share of 75.3% as of 2021. With growing dental graft surgeries performed annually, clinics are gaining popularity due to its convenience, and easy availability of surgeons. Compared to hospitals, these clinics are specialized to deliver safer and quicker same-day procedures. Moreover, growing awareness regarding oral health is further propelling the market.
Private dental clinics or specialty clinics are present in large numbers and typically have skilled practitioners specializing in bone grafting procedures. Manufacturing companies have a wide delivery network and target dental clinics primarily through direct sales; multiple smaller clinics tend to collectively bring in more customers than a single hospital. For instance, the Institute Straumann stated in its annual report that its professionals primarily operated in 1,300 dental clinics, as of 2020, and place 300,000 implants annually.
The hospital segment is anticipated to witness lucrative growth during the forecast period. The growth can be attributed to the availability of a wide range of reconstructive procedures under these facilities. Few hospitals are self-funded and are associated with tissue banks aiming to provide class-leading services. Moreover, hospitals collaborate with various insurance companies for better and fast reimbursement. Owing to all these benefits the overall footfall in hospitals is more as compared to clinics.
Regional Insights
North America dominated the global dental bone grafts & substitutes market in terms of revenue share in 2021. The increasing target population and the increasing number of dental implant surgeries in this region are driving the growth. Europe held the second-largest share and is expected to show significant growth in the coming years. The Asia Pacific region is expected to show lucrative growth during the forecast period. The growth can be attributed to an increased number of medical tourism and government initiatives.
Moreover, a growing aging population in the Asia Pacific region is further increasing the risk of dental problems. On the contrary, stringent regulatory guidelines in some countries can limit growth in the near future. In South Korea, the product should be approved by the Korean Food and Drug Administration (KFDA) before marketing. In the case of Australia, the graft products are regulated by Therapeutic Goods Administration (TGA). The stringent regulatory scenario in these countries creates a barrier for foreign players to enter the market.
Medical tourism in India & China for dental grafting surgeries is another growth propelling factor for the market. In addition, the availability of resources that enable the development of advanced end-use at a cheaper cost is resulting in an increased number of manufacturing facilities in these countries. China has released Order 650 (former Order 276), Regulations for the Supervision and Administration of Medical Devices, to restrict foreign investment in the country, mainly to protect the domestic medical devices manufacturing industry. As a result, the number of local bone graft manufacturers is anticipated to grow in near future.
Key Players
- Dentsply Sirona
- Biohorizons Inc.
- Zimmer Biomet
- Dentsply Sirona
- RtiSurgicals
- Medtronic
- Geistlich Pharma Ag
- Dentium Co, Ltd.
- Orthogen.
- Lifenet Health
Market Segmentation
- By Material Type Outlook
- Allograft
- Demineralized Bone Matrix
- Others
- Xenograft
- Synthetic
- Autograft
- Allograft
- By Application Outlook
- Ridge Augmentation
- Sinus Lift
- Periodontal Defect Regeneration
- Implant Bone Regeneration
- Socket Preservation
- By End-use Outlook
- Hospitals
- Dental clinics
- By Regional Outlook
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Click Here to View Full Report Table of Contents
Full Report is Ready | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39235
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333